NUVALENT INC-A (NUVL) Stock Price, Quote, News and Overview
NASDAQ:NUVL - Nasdaq - US6707031075 - Common Stock - Currency: USD
NUVL Quote, Performance and Key Statistics
79.49
-2.9 (-3.52%)
The current stock price of NUVL is 79.49 USD. In the past month the price decreased by -5.03%. In the past year, price decreased by -8.9%.
NUVL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NUVL
Company Profile
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 127 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. The company is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Company Info
NUVALENT INC-A
One Broadway, 14Th Floor
Cambridge MASSACHUSETTS US
CEO: James R. Porter
Employees: 115
Company Website: https://www.nuvalent.com/
Investor Relations: https://investors.nuvalent.com/
Phone: 18573577000
NUVALENT INC-A / NUVL FAQ
What is the stock price of NUVALENT INC-A today?
The current stock price of NUVL is 79.49 USD. The price decreased by -3.52% in the last trading session.
What is the ticker symbol for NUVALENT INC-A stock?
The exchange symbol of NUVALENT INC-A is NUVL and it is listed on the Nasdaq exchange.
On which exchange is NUVL stock listed?
NUVL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NUVALENT INC-A stock?
20 analysts have analysed NUVL and the average price target is 117.34 USD. This implies a price increase of 47.61% is expected in the next year compared to the current price of 79.49. Check the NUVALENT INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NUVALENT INC-A worth?
NUVALENT INC-A (NUVL) has a market capitalization of 5.65B USD. This makes NUVL a Mid Cap stock.
How many employees does NUVALENT INC-A have?
NUVALENT INC-A (NUVL) currently has 115 employees.
What are the support and resistance levels for NUVALENT INC-A (NUVL) stock?
NUVALENT INC-A (NUVL) has a support level at 78.99 and a resistance level at 81.34. Check the full technical report for a detailed analysis of NUVL support and resistance levels.
Should I buy NUVALENT INC-A (NUVL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NUVL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NUVL, evaluating the profitability, health, valuation and growth aspects
- NUVALENT INC-A (NUVL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUVALENT INC-A (NUVL) Sales and EPS estimates to see what analysts future expectations are.
- NUVALENT INC-A (NUVL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUVALENT INC-A (NUVL) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUVALENT INC-A (NUVL) Stock Chart to make your own analysis
- NUVALENT INC-A (NUVL) Latest news and press-releases to stay up to date.
Does NUVALENT INC-A (NUVL) stock pay dividends?
NUVL does not pay a dividend.
What is the Price/Earnings (PE) ratio of NUVALENT INC-A (NUVL)?
NUVALENT INC-A (NUVL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.47).
What is the Short Interest ratio of NUVALENT INC-A (NUVL) stock?
The outstanding short interest for NUVALENT INC-A (NUVL) is 9.45% of its float. Check the ownership tab for more information on the NUVL short interest.
NUVL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NUVL. When comparing the yearly performance of all stocks, NUVL is a bad performer in the overall market: 79.45% of all stocks are doing better.
NUVL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NUVL. No worries on liquidiy or solvency for NUVL as it has an excellent financial health rating, but there are worries on the profitability.
NUVL Financial Highlights
Over the last trailing twelve months NUVL reported a non-GAAP Earnings per Share(EPS) of -3.47. The EPS decreased by -70.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.87% | ||
| ROE | -20.01% | ||
| Debt/Equity | 0 |
NUVL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to NUVL. The Buy consensus is the average rating of analysts ratings from 20 analysts.